公衆衛生

Age-related hearing loss is a potential risk factor for dementia. While some studies have indicated a specific link to Alzheimer's disease, the relationship between hearing loss and amyloid-β (Aβ) pathology remains inconclusive. This is further complicated by animal studies reporting a bidirectional relationship. The current study aimed to clarify the association between hearing loss and Aβ, and its directionality, in a human setting of community dwelling subjects.

At baseline, single molecule array plasma measures of Aβ42/40 and pTau217 were collected from 474 participants of the prospective population-based Rotterdam Study (mean age = 62.37, 51.3% female). Participants underwent pure-tone audiometry, using the pure-tone average (PTA) of the better hearing ear as a measure for age-related hearing loss. After on average seven years, these participants underwent amyloid 18F-florbentaben PET. Two years after PET, PTA was measured a second time (Figure 1A). We investigated the association between (1) PTA at baseline and (2) changes in PTA with the risk of plasma-negative participants (baseline pTau217<0.63 pg/mL, n = 461) converting to amyloid PET positivity during follow-up (Figure 1B). We also studied the reverse relationship whether plasma biomarkers at baseline contribute to changes in PTA over time.

Baseline PTA was not a significant predictor of incident amyloid PET positivity seven years later (OR=0.96 [0.72, 1.28], p = 0.780). Similarly, yearly rate of change in PTA showed no association with incident amyloid PET positivity (OR=0.99 [0.72, 1.36], p = 0.952). Furthermore, no significant association was observed between baseline plasma biomarkers and change in PTA over time (Aβ42/40*time: β=0.0 [-0.005, 0.006], p = 0.926; pTau217*time: β=0.001 [-0.004, 0.007], p = 0.659.

In this longitudinal cohort study, we found no (bidirectional) association between age-related hearing loss and Aβ pathology. Our results suggest that hearing loss may increase dementia risk through other pathways than Aβ pathology.